David Evans is the Interim Chief Executive Officer of Guardion Health Sciences, a company focused on innovative health products. He joined the company as a director in 2017 after the acquisition of his company, VectorVision, which specializes in vision testing....
David Evans is the Interim Chief Executive Officer of Guardion Health Sciences, a company focused on innovative health products. He joined the company as a director in 2017 after the acquisition of his company, VectorVision, which specializes in vision testing. With a strong background in clinical contrast sensitivity and glare testing, David has made significant contributions to optics and vision science, publishing over 30 scientific articles and holding multiple patents. His experience includes working as Chief Science Officer and leading key projects at Guardion. In 2020, he stepped in as Interim CEO, showing his capability to lead during crucial times. Despite no bonuses or stock grants during his tenure, his commitment to consulting work has been a vital asset. His salary was modest, totaling $236,931 in 2021, which included $208,282 from his base salary and other compensation. Notably, he controls a substantial portion of the company’s stocks through VectorVision, where he holds 28% of shares. David's unique blend of scientific expertise and leadership in health-related advancements defines his role at Guardion.